Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

NCT04243109 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Low recruitment rate. Lack of interest of the sponsor.

Conditions

Multiple Myeloma

Interventions

DRUG: Pomalidomide + Cyclophosphamide + Dexamethasone

Sponsor

Maimónides Biomedical Research Institute of Córdoba